Diffusion Basis Spectrum Imaging (DBSI) probes axonal and myelin damage by modeling the diffusion-weighted MRI signal as discrete anisotropic diffusion tensors while simultaneously differentiating and quantifying inflammation and edema through a modeled isotropic diffusion tensor spectrum. We studied 15 RMS patients beginning ocrelizumab treatment over two years as well as 10 healthy controls.
DBSI detected microstructural differences between RMS normal-appearing white matter, chronic and enhancing lesions, and healthy control white matter. Further, the metrics were sensitive to changes within two years of follow-up and showed improvement towards healthy control values in patients treated with ocrelizumab.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords